Prostate cancer is the cancer that occurs in the male's prostate.
It is the most common cancer in men >50 years of age.
Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.
Olaparib, a PARP* inhibitor used to treat ovarian and breast cancer, also extends overall survival (OS) of men with metastatic castration-resistant prostate cancer (mCRPC) harbouring at least one mutation in BRCA1, BRCA2, or ATM, according to final report of the PROfound** study presented at ESMO 2020.
The addition of enzalutamide to androgen deprivation therapy (ADT) improved overall survival (OS) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC), demonstrated the phase III PROSPER* trial.
Prostate-specific membrane antigen (PSMA) PET-CT offers superior accuracy in identifying pelvic nodal or distant-metastatic disease in men with high-risk prostate cancer and may be a suitable replacement for conventional imaging with CT combined with bone scan, according to results of the proPSMA study.
Cabazitaxel is maximally effective against castration-resistant prostate cancer (CRPC) if used early, before disease progression, a recent study has shown. Dosing should be maintained carefully, however, because of the possibility of side effects.
The addition of apalutamide, a novel androgen receptor inhibitor, to androgen deprivation therapy (ADT) reduced the risk of progression while on first subsequent therapy or death (PFS2) in men with metastatic castration-sensitive prostate cancer (mCSPC), according to exploratory analysis of the phase III TITAN* trial.
In addition to extending survival, cabazitaxel also improves pain and quality of life (QoL) compared with abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), results from the phase III CARD* trial showed.
Use of complementary and alternative medicine (CAM) is common among patients with prostate cancer and has seen an increase among those who are newly diagnosed with the disease, a study has shown. Multivitamins and omega-3 fatty acids are the most commonly used CAMs from 1996 to 2016, while vitamin D use has increased dramatically from 2006 to 2010.
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
There appears to be an association between low muscle mass and increased risks of recurrence and mortality in patients who undergo radical prostatectomy of prostate cancer regardless of the body mass index (BMI), suggests a recent study.
While most patients do not have such concerns, some young men treated for testicular cancer experience sexual dysfunction and other reproductive concerns 2 years after diagnosis, a recent study has found.
Coadministration of DHA and vitamin E supplements results in increased sperm motility, but no significant changes have been observed in sperm morphology and vitality in asthenozoospermic men, a study has shown.